First episode or first re-occurrence of C. Diff infection
Clinical Trials
Ongoing Study Opportunities
The medical world is constantly advancing and developing new treatments for various disease processes. Speak with your gastroenterologist to see what study may be right for you. Please check back frequently for newly enrolling studies.
If you are interested in a clinical trial, contact our office at 440-205-1225 ext 6. Our study coordinator can provide you with the information you need or answer questions you may have.
C. Diff (Clostridioides Difficile)
50/50 Treatment to Placebo, oral capsule, 33-week study, in combination with SOC antibiotics.
Colorectal Cancer Screenings (CRC)
45 years old or older, first-time colonoscopy or at least 9 years since your last colonoscopy. Participant must not be having GI symptoms that may need to be investigated by physician
Stool Collection Testing
Blood Collection Testing
Blood and Stool Collection Testing
Crohn's Disease
Must have been diagnosed for at least 3 months, currently experiencing symptoms such as abdominal pain, frequent loose stools, urgency etc., and failed to respond to steroid, immunosuppression, or a biologic therapy
(TAK-279) Small molecule allosteric inhibitor with highly selective to JH2, Oral pill.
(MK-7240) IgG1k monoclonal antibody that blocks binding of TL1A. IV then SC. 52 week study.
Eosinophilic Esophagitis (EOE)
Already been diagnosed with EOE and having symptoms such as difficulty swallowing at least 2 days per week and have failed standard of care treatment such as PPI, swallowed steroids, or an elimination diet
Anti-KIT IGGI Tyrosine Kinase
A protein that blocks cells that cause inflammation subcutaneous injection, 50 week study, open label after 12 weeks, meaning no placebo after first 12 weeks
Irritable Bowel Syndrome - Diarrhea
Inclusion: Have abdominal pain at least 2x a week with >25% of Bowel Movements being loose, watery stools. A colonoscopy is required if above age 45. Exclusion: Does not have constipation. No Personal history of Irritable bowel disease or in a 1st degree relative. *Other Criteria Apply*
66% chance of treatment, 33% chance of placebo, antispasmodic oral capsules, 19-week study.
Liver Study - NAFLD (Non-Alcoholic Fatty Liver Disease) or NASH (Non-Alcoholic Steatohepatitis)
Must have a BMI >30 kg, Diabetic Type II, on stable dose of DPP-4/sgl-2 with HgbA1C stable between 6.5-10.5%, must have attempted weight loss once in the last 6 years, possibly willing to undergo Fibroscans, MRIs, and liver biopsy.
Oral pill, investigational product expected to improve metabolism, steatosis, inflammation, fibrosis, and vasculature to liver, part 1: 2 out of 3 chance to receive investigational product for up to 72 weeks, part 2: open label (no placebo) up to 7 years
Oral pill, investigational product works by increasing mitochondrial inefficiency and expected to prevent progression of NASH, reduction of body and liver weight, reduction of liver histology hallmarks of NASH, 26-week study
Liver Study - Prevention of Overt Hepatic Encephalopathy
Must have a diagnosis of liver cirrhosis with medically controlled ascites not requiring a paracentesis in the last 30 days
Oral pill, 80 week study with 50% chance of receiving investigational product versus placebo
Upcoming Study Opportunities
Crohn's Disease
Must have been diagnosed for at least 3 months, currently experiencing symptoms such as abdominal pain, frequent loose stools, urgency etc., and failed to respond to steroid, immunosuppression, or a biologic therapy
(VEDO4051) 76-week study, Dual Therapy, IV & SC.
